📇 Rhumatologue · VALENCIENNES · (59) · Libéral

MME Manuele BERREBI-DELMOTTE

Pourquoi vous devez consulter ce praticien

4 raisons identifiées

Auteur de référence en rhumatologie
36 articles scientifiques publiés — un praticien à la pointe de la recherche
Cabinet de groupe — continuité de soins
Plusieurs praticiens dans le même cabinet — un confrère peut prendre le relais en cas d'absence
Disponibilité géographique
6 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
126.7 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 VALENCIENNES (59)LibéralRPPS 10003455721

✨ Génération du profil synthétique IA en cours…

Lieux de consultation(6)

SELAS IMALLIANCE HDF
9 AVENUE DES DENTELLIERES, 59300 VALENCIENNES
Activité de soin et de pharmacie
SELAS IMALLIANCE HDF
108 AVENUE DE LA LIBERATION, 59310 ORCHIES
Activité de soin et de pharmacie
SELAS IMALLIANCE HDF
CENTRE HOSPITALIER 25 B AVENUE JEAN JAURES, 59220 DENAIN

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Associations between paternal versus maternal parenting behaviors and child and adolescent internalizing problems: A systematic review and meta-analysis

Clinical psychology review · 2023

📚 46 citations🎯 RCR 10.73Top 2% NIH🔓 Open Access

Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study

Frontiers in medicine · 2021

📚 25 citations🎯 RCR 1.34🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Background: Protease inhibitors have been considered as possible therapeutic agents for COVID-19 patients.Objectives: To describe the association between lopinavir/ritonavir (LPV/r) or darunavir/cobicistat (DRV/c) use and in-hospital mortality in COVID-19 patients.Study Design: Multicenter observational study of COVID-19 patients admitted in 33 Italian hospitals. Medications, preexisting conditions, clinical measures, and outcomes were extracted from medical records. Patients were retrospectively divided in three groups, according to use of LPV/r, DRV/c or none of them. Primary outcome in a time-to event analysis was death. We used Cox proportional-hazards models with inverse probability of treatment weighting by multinomial propensity scores.Results: Out of 3,451 patients, 33.3% LPV/r and 13.9% received DRV/c. Patients receiving LPV/r or DRV/c were more likely younger, men, had higher C-reactive protein levels while less likely had hypertension, cardiovascular, pulmonary or kidney disease. After adjustment for propensity scores, LPV/r use was not associated with mortality (HR = 0.94, 95% CI 0.78 to 1.13), whereas treatment with DRV/c was associated with a higher death risk (HR = 1.89, 1.53 to 2.34, E-value = 2.43). This increased risk was more marked in women, in elderly, in patients with higher severity of COVID-19 and in patients receiving other COVID-19 drugs.Conclusions: In a large cohort of Italian patients hospitalized for COVID-19 in a real-life setting, the use of LPV/r treatment did not change death rate, while DRV/c was associated with increased mortality. Within the limits of an observational study, these data do not support the use of LPV/r or DRV/c in COVID-19 patients.

Phase IV postmarketing surveillance study shows continued efficacy and safety of Stempeucel in patients with critical limb ischemia due to Buerger's disease

Stem cells translational medicine · 2021

📚 17 citations🎯 RCR 1.35🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Buerger's disease or thromboangiitis obliterans is a type of obstructive vascular diseases categorized as vasculitis and usually present in 95% of young smoker men. The main pathogenetic mechanism is interplay between immune system and inflammation. Earlier our phase II study has shown that Stempeucel is safe when injected at 2 million cells/kg body weight by virtue of its anti-inflammatory, immunomodulatory, and angiogenetic properties. The present study was conducted to further assess the safety and efficacy of Stempeucel in critical limb ischemia due to Buerger's disease after obtaining approval from Indian FDA based on the data generated in the phase II study. This is an open label, multicenteric phase IV PMS study conducted across India with experienced vascular surgeons. Fifty patients of critical limb ischemia due to Buerger's disease with Rutherford III-5 or III-6 were included in the study and each individual received a dose of 2 million cells/kg body weight of Stempeucel in the calf muscles and around the ulcer. These patients were evaluated over 12 months from drug administration. The present study showed the continued long term efficacy over a period of 12 months follow up in these patients corroborating the result obtained in the previous phase II studies. There was significant improvement in rest pain, ankle systolic pressure, and ankle brachial pressure index with accelerated ulcer healing. In conclusion, the present study shows that the intramuscular administration of Stempeucel continues to be safe, tolerable, and effective alternative treatment in patients with Buerger's disease.

Cookies & analyse de trafic

MME Manuele BERREBI-DELMOTTE

Pourquoi vous devez consulter ce praticien

Lieux de consultation(6)

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (36) — classées par pathologie

Transversal10

Pédiatrie3

Arthrite juvénile2

csDMARDs2

Épidémiologie & registres2

Essai clinique2

Revue générale2

Vascularites des gros vaisseaux2

Vraie vie / RWE2

Économie santé1

Génétique1

JAK inhibiteurs1

Lombalgie1

Lupus1

Maladie à IgG41

Pharmacovigilance1

Qualité de vie / PROMs1

Revue / méta-analyse1

Sjögren1

Tendinopathies & SCC1

Vascularites1

Partager cette fiche